DT Cloud收购公司与Maius制药有限公司在250M交易中合并,组成Maius制药集团有限公司,侧重于创新药物开发。 DT Cloud Acquisition Corporation merges with Maius Pharmaceutical Co. Ltd. in a $250M deal, forming Maius Pharmaceutical Group Co. Ltd. and focusing on innovative drug development.

DT云采购公司已宣布与一家生物制药研发公司Maius制药有限公司合并。 DT Cloud Acquisition Corporation has announced a merger with Maius Pharmaceutical Co., Ltd., a biopharmaceutical R&D firm. 这项价值2.5亿美元的交易将在完成后创建Maius制药集团有限公司,预期在2025年上半年完成,等待监管和股东批准。 The deal, valued at $250 million, will create Maius Pharmaceutical Group Co. Ltd. upon completion, expected in the first half of 2025, pending regulatory and shareholder approvals. 新实体将侧重于开发肿瘤学、天免疫机能失调和传染病方面的创新药物,并将在Nasdaq的新标志下进行贸易。 The new entity will focus on developing innovative drugs in oncology, autoimmune disorders, and infectious diseases, and will trade under a new symbol on Nasdaq.